Root Financial Partners
PTGX icon

Root Financial Partners’s Protagonist Therapeutics PTGX Stock Holding History

Root Financial Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$845 Buy
+6
New +$855 ﹤0.01% 3024
2026
Q2 		– Sell
-3
Closed -$316 – 2483
2026
Q1 		$316 Hold
3
– – ﹤0.01% 3017
2025
Q4 		$262 Buy
+3
New +$246 ﹤0.01% 2277

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

Root Financial Partners's PTGX Position: Q3 2026 in Review

Root Financial Partners opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 6 shares worth $845. The stake represents ﹤0.01% of the portfolio and ranks #3024 among its holdings. This is a return to the name: Root Financial Partners previously reported a position in PTGX as recently as Q1 2026.

Root Financial Partners first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Root Financial Partners held 6 shares of Protagonist Therapeutics worth $845 as of Q3 2026.
  • Protagonist Therapeutics was a new Root Financial Partners position in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3024 holding.
  • Root Financial Partners first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.